Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With Thymidine Kinase 2 Deficiency (TK2)

NCT03845712 is registered in ClinicalTrials.gov with UCB BIOSCIENCES, Inc. as lead sponsor.

NCT NCT03845712
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03845712 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With Thymidine Kinase 2 Deficiency (TK2)
Lead sponsor
UCB BIOSCIENCES, Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 5, 2019
Completion date
August 26, 2026
Enrollment
47 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

thymidine kinase 2 deficiency